Financials in USD. Standardized financial statements.
A compact view of how StemGen, Inc. turns revenue into operating income and net income.
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $39,000 | $19,350 | $22,058 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +101.6% | -12.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $30,454 | $8,572 | $8,510 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $8,546 | $10,778 | $13,548 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin? | +21.9% | +55.7% | +61.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $252,470 | $77,848 | $256,734 | $32,325 | $7,549 | $341,228 | $339,085 | $51,183 | $60,202 | $27,710 |
| Operating Income? | -$244,000 | -$67,070 | -$243,000 | -$32,325 | $7,549 | -$341,000 | -$489,000 | -$51,183 | -$60,202 | -$27,710 |
| EBITDA? | -$179,866 | -$70,599 | -$308,000 | $97,684 | $7,549 | -$324,000 | -$489,000 | -$51,183 | -$27,702 | -$27,710 |
| Income Before Tax | -$433,000 | -$230,772 | -$426,000 | $6,115 | -$70,003 | -$600,000 | -$492,000 | $16,420 | -$88,419 | -$68,370 |
| Income Tax Expense | $0 | $0 | $0 | $0 | -$2 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$433,000 | -$230,772 | -$426,000 | $6,115 | -$70,001 | -$600,000 | -$492,000 | $16,420 | -$88,419 | -$68,370 |
| EPS? | $-0.01 | $-0.01 | $-0.02 | $0.00 | $-0.01 | $-0.04 | $-0.05 | $0.00 | $-0.49 | $-0.42 |
| Diluted EPS? | $-0.01 | $-0.01 | $-0.02 | $0.00 | $-0.01 | $-0.04 | $-0.05 | $0.00 | $-0.49 | $-0.42 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality